RIMSO-50 Shortage Update: What Patients Need to Know in 2026

For patients with interstitial cystitis (IC), RIMSO-50 (dimethyl sulfoxide) is not just another medication — it is the only FDA-approved bladder instillation therapy specifically for their condition. When it becomes difficult to obtain, the consequences are immediate and painful. This article covers the current availability status of RIMSO-50, why patients sometimes struggle to find it, and what you should do in 2026 if your supply is disrupted.

Current RIMSO-50 Availability Status in 2026

As of 2026, RIMSO-50 does not appear on the FDA's official Drug Shortages list as an active shortage. However, the absence of an official shortage designation can be misleading. The FDA formally designates shortages primarily for drugs that are in widespread, critical supply crises. Regional or localized supply issues — where the drug is technically available nationally but hard to find at a specific clinic or in a specific region — often go unreported.

Many RIMSO-50 patients and their providers continue to report difficulty obtaining the drug on schedule. This is a structural availability problem related to the drug's specialty supply chain, not necessarily a manufacturer crisis.

Understanding RIMSO-50's Unique Supply Chain

RIMSO-50 is not a retail pharmacy drug. Because it must be administered by a healthcare provider through intravesical catheterization, it travels through a specialty supply chain:

Manufacturer (Mylan or Sandoz generic) → Specialty wholesale distributors → Hospital pharmacies / Urology clinic supply chains

This specialty pathway means that while overall national supply may be adequate, individual clinics may run out between ordering cycles, and patients in rural or underserved areas may face consistent access challenges.

Historical Background: Has RIMSO-50 Had Shortage Problems Before?

RIMSO-50 has a complicated history. As a niche specialty drug approved since 1978 with a relatively small patient population, it has periodically experienced supply disruptions tied to manufacturing changes, distributor issues, and changes in ownership. The drug has traded hands between various pharmaceutical companies over the decades, and each transition has sometimes created temporary supply gaps.

Additionally, clinicians at the AUA 2013 Annual Meeting raised a serious consumer safety concern: at least one compounding pharmacy in the U.S. had been shipping industrial-grade DMSO — not pharmaceutical-grade RIMSO-50 — to urology clinics. This type of error underscores the fragility of the specialty supply chain and the importance of confirming the source and purity of the product being administered.

What Are the Warning Signs of a Supply Problem at Your Clinic?

Patients should watch for these signs that their clinic may be having RIMSO-50 supply issues:

Your appointment is delayed or rescheduled without a clear reason

The clinic asks you to wait "a few more weeks" before your next instillation

You are offered a different treatment without explanation of why RIMSO-50 is not being used

Clinic staff seem uncertain about when the medication will be available

In any of these scenarios, ask directly: "Is there a supply issue with RIMSO-50?" and "Are you using pharmaceutical-grade RIMSO-50 or the Sandoz generic?" You have the right to know what medication is being used in your treatment.

What Patients Should Do If They Can't Get RIMSO-50 in 2026

Verify the official FDA shortage database: Check FDA.gov/drugs/drug-shortages for the current status of dimethyl sulfoxide.

Ask about generic alternatives: Sandoz's generic dimethyl sulfoxide solution is equivalent and may be available when RIMSO-50 brand is not.

Contact specialty pharmacies: Hospital pharmacies or dedicated specialty pharmacies may have stock when your urology clinic does not.

Use medfinder: Let medfinder contact pharmacies in your area to check which ones have RIMSO-50 in stock. You provide your information, and results are texted to you.

Talk to your provider about bridge therapy: See our guide on RIMSO-50 alternatives for options including intravesical heparin, lidocaine cocktails, and oral IC medications.

Advocating for Yourself as an IC Patient

Interstitial cystitis is already a condition that is sometimes dismissed or misunderstood by the medical community. Add in a medication that is difficult to find, and patients can feel overwhelmed. Document your treatment history, communicate openly with your provider about availability concerns, and do not hesitate to seek a second opinion from a urology center that specializes in IC if your needs are not being met.